Back

SGLT2 inhibitors: beyond their glucose-lowering effects.

17 April 2021 (16:54 - 17:01)
Organised by:
Congress Presentation Part of: Dyslipidaemia and type 2 diabetes - the two ugly sisters Lipids Open Access ESC Preventive Cardiology 2021

About the speaker

Photo
Professor Angelo Avogaro

Padova Hospital, Padova (Italy)

4 More presentations in this session

Presentation thumbnail
Dyslipidaemia in type 2 diabetes: scope of the problem.
Professor F. Mach (Geneva, CH)
Video
Presentation thumbnail
When statins are not enough: emerging pharmacological tools.
Professor U. Landmesser (Berlin, DE)
Video
Presentation thumbnail
Triglyceride-rich lipoproteins: is weight loss the solution?
Professor J. Armitage (Oxford, GB)
Video
Presentation thumbnail
Dyslipidaemia and type 2 diabetes - the two ugly sisters - discussion.

Access the full session

Session thumbnail
Dyslipidaemia and type 2 diabetes - the two ugly sisters
Video

The Event

Event poster

ESC Preventive Cardiology 2021

17 April 2021 16:54 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 Inhibitors in patients with cancers
20 June 2025
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
19 May 2025
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources